|
|
 Previous Article | Table of Contents | Next Article 
Preparation and successful engraftment of purified CD34+ bone marrow
progenitor cells in patients with non-Hodgkin's lymphoma
NC Gorin, M Lopez, JP Laporte, P Quittet, S Lesage, F Lemoine, RJ Berenson, F Isnard, M Grande and J Stachowiak
Departement of Hematology, Unite de recherches sur les greffes de cellules
souches hematopoiuauetiques, Lille, France.
From September 1992 to January 1994, we evaluated the use of the CEPRATE SC
stem cell concentrator (CellPro, Inc, Bothell, WA) to select CD34+ cells
from the bone marrow (BM) of 25 patients with non-Hodgkin's lymphoma in
complete remission. This system uses the biotinylated 12.8 IgM MoAb to
select CD34+ cells. Cells are retained on an avidin column and detached by
agitation. Fifteen patients have been transplanted with the CD34+ purified
fraction. The CD34+ purified fraction of the 25 processed BMs contained a
median of 0.54% of the original nucleated cells in a volume of 5 to 10 mL.
The median concentration of CD34+ cells was 49% (range, 12% to 80%), and
the median enrichment of CD34+ cells was 33-fold (range, 9- to 85-fold).
This selected CD34+ fraction retained 60% (range, 15% to 95%) of late
granulocyte-macrophage colony- forming units (CFU-GM), 55% (range, 12% to
99%) of early CFU-GM, and 31% (range, 2% to 100%) erythroid burst-forming
units (BFU-E) corresponding to median enrichments of 22-fold (range, 1- to
71-fold), 19-fold (range, 2- to 58-fold), and 14-fold (range, 2- to
200-fold), respectively. There was a correlation between immune phenotypes
and progenitor cells. In the initial buffy-coat fractions, the percentage
of CD34+ cells was correlated to the cloning efficiency of both late CFU-GM
(P < .05) and early CFU-GM (P < .001). In the final selected
fraction, there was a correlation between the percentage of CD34+/CD33- and
the cloning efficiency of early CFU-GM (P < .05) and between the
percentage of CD34+/CD33+ and the cloning efficiency of late CFU-GM (P <
.05). Lymphoma cells positive for t(14; 18) were found by polymerase chain
reaction in 9 of 14 buffy coats tested before CD34+ cell purification. In 8
cases, the CD34(+)-selected fraction was found to be negative, and the
CD34- fraction was found to be positive. After cryopreservation, the
recoveries of progenitor cells in the CD34(+)- purified fraction were 79%
for late CFU-GM, 71% for early CFU-GM, and 73% for BFU-E. The 15 patients
transplanted with the concentrated CD34+ fraction received a median dose of
1 x 10(6) CD34+ cells/kg (range, 0.3 to 2.96) and 10.62 x 10(4) early
CFU-GM/kg (range, 0.92 to 25.55). Median days to recovery to 0.5 x 10(9)/L
neutrophils and 50 x 10(9)/L platelets were days 15 (range, 10 to 33) and
23 (range, 11 to 68), respectively.(ABSTRACT TRUNCATED AT 400 WORDS)
Volume 85,
Issue 6,
pp. 1647-1654,
03/15/1995
Copyright © 1995 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Hunault-Berger, N. Ifrah, and P. Solal-Celigny
Intensive therapies in follicular non-Hodgkin lymphomas
Blood,
July 30, 2002;
100(4):
1141 - 1152.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Lemoli, G. Martinelli, E. Zamagni, M. R. Motta, S. Rizzi, C. Terragna, R. Rondelli, S. Ronconi, A. Curti, F. Bonifazi, et al.
Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy
Blood,
April 1, 2000;
95(7):
2234 - 2239.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Apostolidis, R. K. Gupta, D. Grenzelias, P. W. M. Johnson, V. I. Pappa, K. E. Summers, A. Salam, K. Adams, A. J. Norton, J. A. L. Amess, et al.
High-Dose Therapy With Autologous Bone Marrow Support as Consolidation of Remission in Follicular Lymphoma: Long-Term Clinical and Molecular Follow-Up
J. Clin. Oncol.,
February 1, 2000;
18(3):
527 - 527.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Vescio, G. Schiller, A. K. Stewart, O. Ballester, S. Noga, H. Rugo, C. Freytes, E. Stadtmauer, S. Tarantolo, F. Sahebi, et al.
Multicenter Phase III Trial to Evaluate CD34+ Selected Versus Unselected Autologous Peripheral Blood Progenitor Cell Transplantation in Multiple Myeloma
Blood,
March 15, 1999;
93(6):
1858 - 1868.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Tarella, F. Zallio, D. Caracciolo, C. Cherasco, P. Bondesan, P. Gavarotti, P. Corradini, V. Tassi, and A. Pileri
Hemopoietic Progenitor Cell Mobilization and Harvest Following an Intensive Chemotherapy Debulking in Indolent Lymphoma Patients
Stem Cells,
January 1, 1999;
17(1):
55 - 61.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
G. Tricot, Y. Gazitt, T. Leemhuis, S. Jagannath, K.R. Desikan, D. Siegel, A. Fassas, S. Tindle, J. Nelson, C. Juttner, et al.
Collection, Tumor Contamination, and Engraftment Kinetics of Highly Purified Hematopoietic Progenitor Cells to Support High Dose Therapy in Multiple Myeloma
Blood,
June 15, 1998;
91(12):
4489 - 4495.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Rambaldi, G. Borleri, G. Dotti, P. Bellavita, R. Amaru, A. Biondi, and T. Barbui
Innovative Two-Step Negative Selection of Granulocyte Colony-Stimulating Factor-Mobilized Circulating Progenitor Cells: Adequacy for Autologous and Allogeneic Transplantation
Blood,
March 15, 1998;
91(6):
2189 - 2196.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Lopez, F.M. Lemoine, H. Firat, L. Fouillard, J.P. Laporte, S. Lesage, F. Isnard, J. Stachowiak, F. Ferrer-Le Coeur, P. Morel, et al.
Bone Marrow Versus Peripheral Blood Progenitor Cells CD34 Selection in Patients With Non-Hodgkin's Lymphomas: Different Levels of Tumor Cell Reduction. Implications for Autografting
Blood,
October 1, 1997;
90(7):
2830 - 2838.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. W. Lowdell and P. Theocharous
"Less is More": The Role of Purging in Hematopoietic Stem Cell Transplantation
Oncologist,
August 1, 1997;
2(4):
268 - 274.
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Paulus, P. Dreger, K. Viehmann, N. v. Neuhoff, and N. Schmitz
Purging Peripheral Blood Progenitor Cell Grafts from Lymphoma Cells: Quantitative Comparison of Immunomagnetic CD34+ Selection Systems
Stem Cells,
July 1, 1997;
15(4):
297 - 304.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. T. Voso, S. Hohaus, M. Moos, and R. Haas
Lack of t(14; 18) Polymerase Chain Reaction-Positive Cells in Highly Purified CD34+ Cells and Their CD19 Subsets in Patients With Follicular Lymphoma
Blood,
May 15, 1997;
89(10):
3763 - 3768.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Corradini, M. Astolfi, C. Cherasco, M. Ladetto, C. Voena, D. Caracciolo, A. Pileri, and C. Tarella
Molecular Monitoring of Minimal Residual Disease in Follicular and Mantle Cell Non-Hodgkin's Lymphomas Treated With High-Dose Chemotherapy and Peripheral Blood Progenitor Cell Autografting
Blood,
January 15, 1997;
89(2):
724 - 491.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Y. Mapara, I. J. Korner, M. Hildebrandt, R. Bargou, D. Krahl, P. Reichardt, and B. Dorken
Monitoring of Tumor Cell Purging After Highly Efficient Immunomagnetic Selection of CD34 Cells From Leukapheresis Products in Breast Cancer Patients: Comparison of Immunocytochemical Tumor Cell Staining and Reverse Transcriptase-Polymerase Chain Reaction
Blood,
January 1, 1997;
89(1):
337 - 344.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Hassan, W Zeller, M Stockschlader, W Kruger, M. Hoffknecht, and A. Zander
Comparison between bone marrow and G-CSF-mobilized peripheral blood allografts undergoing clinical scale CD34+ cell selection
Stem Cells,
July 1, 1996;
14(4):
419 - 429.
[Abstract]
|
|
|
|
|
|
|
F Servida, D Soligo, L Caneva, F Bertolini, E de Harven, S Campiglio, C Corsini, and G. Deliliers
Functional and morphological characterization of immunomagnetically selected CD34+ hematopoietic progenitor cells
Stem Cells,
July 1, 1996;
14(4):
430 - 438.
[Abstract]
|
|
|
|
|
